No connection

Search Results

PGNY

BULLISH
$17.93 Live
Progyny, Inc. · NASDAQ
Target $27.45 (+53.1%)
$16.1 52W Range $28.75
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$1.47B
P/E
26.76
ROE
12.5%
Profit margin
4.5%
Debt/Equity
0.05
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
PGNY exhibits exceptional fundamental health, highlighted by a perfect Piotroski F-Score of 9/9 and a negligible Debt/Equity ratio of 0.05. While the stock has suffered significant long-term price decay and currently faces bearish technical trends and insider selling, the valuation is highly attractive on a forward basis with a Forward P/E of 8.53. The company's consistent track record of earnings beats and strong earnings growth (20.6% YoY) suggests a disconnect between market sentiment and operational performance. The current price of $17.93 sits comfortably below the growth-based intrinsic value of $19.77 and well below analyst targets.

Key Strengths

Perfect Piotroski F-Score (9/9) indicating peak financial health
Extremely low leverage with a Debt/Equity ratio of 0.05
Strong liquidity position with a Current Ratio of 2.73
Exceptional earnings track record with consistent beats over 25 quarters
Highly attractive Forward P/E of 8.53 compared to current P/E of 26.76

Key Risks

Strongly bearish technical trend (0/100 score)
Bearish insider sentiment with consistent selling by CFO and General Counsel
Modest revenue growth (6.7%) relative to aggressive earnings growth
Significant long-term price depreciation (5Y Change: -63.7%)
Lack of dividend yield for income-seeking investors
AI Fair Value Estimate
Based on comprehensive analysis
$20.5
+14.3% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
58
Moderate
Value
75
Future
82
Past
35
Health
98
Dividend
0
AI Verdict
Strong Fundamental Value Play
Key drivers: Piotroski 9/9, Forward P/E compression, Earnings surprise consistency
Confidence
90%
Value
75/100

P/E 26.76, Forward P/E 8.53, Graham $9.7

Positives
  • Price is below Intrinsic Value ($19.77)
  • Forward P/E is very low (8.53)
Watchpoints
  • Trades at a premium to Graham Number ($9.7)
Future
82/100

Ref Growth rates and Analyst Targets

Positives
  • 20.6% Earnings Growth YoY
  • Strong analyst target price of $27.45
Watchpoints
  • Revenue growth is relatively slow at 6.7%
Past
35/100

Ref Historical price trends

Positives
  • Consistent earnings beats for years
Watchpoints
  • Severe 5-year price decline of 63.7%
  • Negative 1-year return of 16.2%
Health
98/100

Ref Piotroski F-Score and Debt/Equity

Positives
  • Piotroski F-Score 9/9
  • Debt/Equity 0.05
  • Current Ratio 2.73
Watchpoints
  • Altman Z-Score not provided
Dividend
0/100

Ref Yield and Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$17.93
Analyst Target
$27.45
Upside/Downside
+53.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PGNY and closest competitors.

Updated 2026-04-16
PGN
Progyny, Inc.
Primary
5Y
-63.7%
3Y
-45.0%
1Y
-16.2%
6M
-15.9%
1M
-0.7%
1W
+8.5%
GEN
Generate Biomedicines, Inc.
Peer
5Y
-8.8%
3Y
-8.8%
1Y
-8.8%
6M
-8.8%
1M
-5.6%
1W
-16.1%
GLU
Monte Rosa Therapeutics, Inc.
Peer
5Y
-14.8%
3Y
+121.2%
1Y
+344.6%
6M
+113.4%
1M
+4.5%
1W
+5.6%
AVA
Aveanna Healthcare Holdings Inc.
Peer
5Y
-42.4%
3Y
+506.1%
1Y
+26.3%
6M
-14.5%
1M
-9.6%
1W
-1.7%
AHC
AdaptHealth Corp.
Peer
5Y
-72.3%
3Y
-20.2%
1Y
+10.2%
6M
+14.1%
1M
+0.5%
1W
+11.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
26.76
Forward P/E
8.53
PEG Ratio
N/A
P/B Ratio
2.88
P/S Ratio
1.14
EV/Revenue
0.92
EV/EBITDA
12.11
Market Cap
$1.47B

Profitability

Profit margins and return metrics

Profit Margin 4.54%
Operating Margin 7.2%
Gross Margin 23.63%
ROE 12.48%
ROA 8.61%

Growth

Revenue and earnings growth rates

Revenue Growth +6.7%
Earnings Growth +20.6%
Q/Q Revenue Growth +6.69%
Q/Q Earnings Growth +18.5%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.05
Low debt
Current Ratio
2.73
Strong
Quick Ratio
2.62
Excellent
Cash/Share
$3.79

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.3B
Gross Margin
24.1%
Op. Margin
4.8%
Net Margin
3.9%
Total Assets
$0.7B
Liabilities
$0.2B
Equity
$0.5B
Debt/Equity
0.44x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
90%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-26
$0.48
+19.9% surprise
2025-11-06
$0.15
+18.3% surprise
2025-08-07
$0.48
+12.1% surprise

Healthcare Sector Comparison

Comparing PGNY against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
P/E Ratio
26.76
This Stock
vs
90.61
Sector Avg
-70.5% (Discount)
Return on Equity (ROE)
12.48%
This Stock
vs
-101.52%
Sector Avg
-112.3% (Below Avg)
Profit Margin
4.54%
This Stock
vs
-12.47%
Sector Avg
-136.4% (Weaker)
Debt to Equity
0.05
This Stock
vs
3.4
Sector Avg
-98.4% (Less Debt)
Revenue Growth
6.7%
This Stock
vs
124.21%
Sector Avg
-94.6% (Slower)
Current Ratio
2.73
This Stock
vs
4.56
Sector Avg
-40.2% (Weaker)

Similar Companies

Peer comparison within the same industry

PGNY Progyny, Inc.
BULLISH
Mkt Cap
$1.5B
P/E
26.8
ROE
12.5%
Price
$17.93
GENB Generate...
BEARISH
Mkt Cap
$1.5B
P/E
-
ROE
-81.7%
Price
$11.53
 Compare with PGNY
GLUE Monte Rosa...
NEUTRAL
Mkt Cap
$1.4B
P/E
-
ROE
-16.9%
Price
$18.05
 Compare with PGNY
AVAH Aveanna...
BEARISH
Mkt Cap
$1.4B
P/E
18.7
ROE
-%
Price
$6.91
 Compare with PGNY
AHCO AdaptHealth Corp.
BEARISH
Mkt Cap
$1.4B
P/E
-
ROE
-4.3%
Price
$10.6
 Compare with PGNY

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SWARTZ ALLISON
General Counsel
Sell
2026-03-04
599 shares · $10,506
SWARTZ ALLISON
General Counsel
Sell
2026-03-03
6,856 shares · $119,007
SWARTZ ALLISON
General Counsel
Stock Award
2026-03-02
28,409 shares
CLAPP GEOFFREY
Officer
Stock Award
2026-03-02
35,228 shares
CUMMINGS MELISSA B
Chief Operating Officer
Stock Award
2026-03-02
45,454 shares
LIVINGSTON MARK S
Chief Financial Officer
Stock Award
2026-03-02
45,454 shares
ANEVSKI PETER
Chief Executive Officer
Stock Award
2026-03-02
159,091 shares
LIVINGSTON MARK S
Chief Financial Officer
Sell
2025-12-11
459 shares · $11,704
SWARTZ ALLISON
General Counsel
Sell
2025-12-04
530 shares · $13,033
LIVINGSTON MARK S
Chief Financial Officer
Sell
2025-12-02
213 shares · $5,432
SWARTZ ALLISON
General Counsel
Sell
2025-11-28
2,398 shares · $64,434
PAYSON NORMAN
Director
Gift
2025-11-18
50,265 shares
LIVINGSTON MARK S
Chief Financial Officer
Sell
2025-11-17
21,303 shares · $543,226
PAYSON NORMAN
Director
Option Exercise
2025-11-14
36,224 shares · $52,525
ANEVSKI PETER
Chief Executive Officer
Buy
2025-11-13
79,500 shares · $1,930,896
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-10

PGNY filed a definitive proxy statement on April 10, 2026, providing shareholders with necessary information to vote at the company's annual meeting.

8-K
8-K
2026-03-13
10-K
10-K
2026-02-27

PGNY filed its 10-K annual report on February 27, 2026, which includes disclosures regarding its business operations, risk factors, and financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-02-26

PGNY filed an 8-K on February 26, 2026, likely to announce its annual or quarterly financial results.

8-K
8-K
2026-01-12
8-K
8-K
2025-12-17
10-Q
10-Q
2025-11-07

PGNY faces material risks from a fragmented landscape of state and federal laws concerning reproductive rights and fertility benefits, which could impair operational efficiency and growth. These regulatory uncertainties, along with state licensing requirements, may adversely affect the company's overall financial performance.

8-K
8-K
2025-11-06
10-Q
10-Q
2025-08-08

PGNY faces material risks from a fragmented landscape of state and federal laws regarding reproductive rights and fertility benefits, which could hinder operational efficiency and growth. These regulatory uncertainties, along with state licensing requirements, may adversely impact the company's overall financial performance.

8-K
8-K
2025-08-07

PGNY filed an 8-K on August 7, 2025, likely to announce its second-quarter financial results.

8-K
8-K
2025-07-08
8-K
8-K
2025-05-28
10-Q
10-Q
2025-05-09
8-K
8-K
2025-05-08
8-K
8-K
2025-04-11
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
11 analysts
Barclays
2026-03-20
Maintains
Overweight Overweight
Canaccord Genuity
2026-03-11
Maintains
Hold Hold
BTIG
2026-03-05
Maintains
Buy Buy
Keybanc
2026-03-02
Maintains
Overweight Overweight
Truist Securities
2026-03-02
Maintains
Buy Buy
Citizens
2026-01-20
up
Market Perform Market Outperform
Keybanc
2026-01-08
Maintains
Overweight Overweight
Barclays
2025-12-09
init
Overweight
Canaccord Genuity
2025-11-17
Maintains
Hold Hold
Keybanc
2025-11-12
up
Sector Weight Overweight

Past News Coverage

Recent headlines mentioning PGNY from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile